Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patency in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis

Tomihisa Kawasaki; Kazuo Sato; Fukushi Hirayama; Hiroyuki Koshio; Yuta Taniuchi; Yuzo Matsumoto

doi:10.1055/s-0037-1615078

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 79(04): 859-864
DOI: 10.1055/s-0037-1615078

Rapid Communication

Schattauer GmbH

Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patency in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis

Tomihisa Kawasaki

¹From the Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan

,

Kazuo Sato

¹From the Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan

,

Fukushi Hirayama

¹From the Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan

,

Hiroyuki Koshio

¹From the Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan

,

Yuta Taniuchi

¹From the Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan

,

Yuzo Matsumoto

¹From the Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan

› Author Affiliations

Abstract

Summary

We examined the adjunctive effect of a novel factor Xa inhibitor, YM-60828, on vessel patency and blood loss from the operation site after successful thrombolysis with a modified tissue-type plasminogen activator (moPA) in an electrically-induced carotid artery thrombosis model in rats. Five minutes after the induction of occlusive thrombus, a test drug (YM-60828, argatroban, heparin or saline) was administered by i.v. bolus injection followed by continuous infusion. Thrombolysis was induced with moPA by i.v. bolus injection at a dose of 650,000 IU/ kg. YM-60828 at 1 mg/kg i.v. followed by 3 mg/kg/h significantly prevented reocclusion, increased the duration of patency, and improved vessel patency after successful thrombolysis without any significant increase in blood loss from the operation site. Argatroban at 1 mg/kg i.v. followed by 3 mg/kg/h and heparin at 300 U/kg i.v. followed by 150 U/kg/h also significantly improved these parameters, but were accompanied by a significant increase in blood loss. These results suggest that the factor Xa inhibitor YM-60828 may be a potent and useful adjunctive agent with a lower risk of bleeding complications than argatroban and heparin in thrombolytic therapy.

Full Text

References

References
1 Rapold HJ, Lu HR, Wu ZM, Nijs H, Collen D. Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator. Blood 1991; 77: 1020-4.
2 Susawa T, Yui Y, Hattori R, Takahashi M, Aoyama T, Takatsu Y, Sakaguchi K, Yui N, Kawai C. Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis. Jpn Circ J 1987; 51: 431-5.
3 Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-56.
4 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
5 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-23.
6 Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72: 381-6.
7 GUSTO IIA Investigator.. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
8 Yin ET, Wessler S. Investigation of the apparent thrombogenicity of thrombin. Thromb Diath Haemorrh 1968; 20: 465-8.
9 Fioravanti C, Burkholder D, Francis B, Siegl PK, Gibson RE. Anti-thrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis. Thromb Res 1993; 71: 317-24.
10 Hara T, Yokoyama A, Tanaba K, Ishihara H, Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1994; 74: 635-9.
11 Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 314-9.
12 Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishima E, Ikeda T, Matsuda T. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb Haemost 1994; 72: 393-6.
13 Taniuchi Y, Sakai Y, Hisamichi N, Kayama M, Mano Y, Sato K, Hirayama F, Koshio H, Matsumoto Y, Kawasaki T. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost 1998; 79: 543-8.
14 Sato K, Kawasaki T, Hisamichi N, Taniuchi Y, Hirayama F, Koshio H, Matsumoto Y. YM-60828, a newly synthesized potent and selective factor Xa inhibitor, exerts its antithrombotic effect with little prolongation of bleeding time. Br J Pharmacol 1998; 123: 92-6.
15 Sato K, Kawasaki T, Taniuchi Y, Hirayama F, Koshio H, Matsumoto Y. The separation of YM-60828, a newly synthesized potent and selective factor Xa inhibitor, between the antithrombotic effect and the prolongation effect of bleeding time in comparison with conventional anticoagulant agents. Eur J Pharmacol 1998; 339: 141-6.
16 Kawasaki T, Sato K, Sakai Y, Hirayama F, Koshio H, Taniuchi Y, Matsumoto Y. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost 1998; 79: 410-6.
17 Kawasaki T, Katoh M, Kaku S, Gushima H, Takenaka T, Yui Y, Kawai C. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis. Jpn J Pharmacol 1993; 63: 9-16.
18 Kawasaki T, Kawamura S, Katoh S, Takenaka T. Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator. Jpn J Pharmacol 1993; 63: 135-40.
19 Hladovec J. Experimental thrombosis in rats with continuous registration. Thromb Diath Haemorrh 1971; 26: 407-10.
20 Schumacher WA, Steinbacher TE, Heran CL, Megill JR, Durham SK. Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. Thromb Haemost 1993; 69: 509-14.
21 Philip RB, Francey I, Warren BA. Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK744 in a rat model of arterial thrombosis. Haemostasis 1978; 7: 282-93.
22 Schaffer LW, Davidson JT, Vlasuk GP, Dunwiddie CT, Siegl PK. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboon. Arterioscler Thromb 1992; 12: 879-85.
23 Biemond BJ, Friederich PW, Levi M, Vlasuk GP, Buller HR, ten Cate JW. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation 1996; 93: 153-60.
24 Wong PC, Crain Jr EJ, Nguan O, Watson CA, Racanelli A. Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb Res 1996; 83: 117-26.
25 Yamashita T, Tsuji T, Matsuoka A, Giddings JC, Yamamoto J. The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res 1996; 85: 45-51.
26 Mellott MJ, Holahan MA, Lynch JJ, Vlasuk GP, Dunwiddie CT. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Circ Res 1992; 70: 1152-60.
27 Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Circulation 1992; 85: 805-15.
28 Mellott MJ, Stranieri MT, Sitko GR, Stabilito II, Lynch JJ, Vlasuk GP. Enhancement of recombinant tissue plasminogen activator-induced reperfusion by recombinant tick anticoagulant peptide, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Fibrinolysis 1993; 7: 195-202.
29 Kawasaki T, Kaku S, Sakai Y, Takenaka T. Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis. J Pharm Pharmacol 1996; 48: 1041-8.
30 Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991; 614: 193-213.
31 Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, Szalony JA, Haas NF, King LW, Zablocki JA, Keller BT, Broschat K, Engleman VW, Herin M, Jacqmin P, Feigen LP. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 1995; 91: 403-10.
32 Zahger D, Fishbein MC, Garfinkel LI, Shah PK, Forrester JS, Regnstrom J, Yano J, Cercek B. VCL, an antagonist of the platelet GPIb receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. Circulation 1995; 92: 1269-73.
33 Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-22.
34 Ramjit DR, Lynch Jr JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD, Chang CT-C, Nutt RF, Brady SF, Veber DF, Anderson PS, Shebuski RJ, Friedman PA, Gould RJ. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis. J Pharmacol Exp Ther 1993; 266: 1501-11.
35 Fujimura Y, Ikeda Y, Miura S, Yoshida E, Shima H, Nishida S, Suzuki M, Titani K, Taniuchi Y, Kawasaki T. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib. Thromb Haemost 1995; 74: 743-50.
36 Sobel BE. Intracranial bleeding, fibrinolysis, and anticoagulation. Causal connections and clinical implications. Circulation 1994; 90: 2147-51.